180 Life Sciencesの推定成長EPS Q/Q
180 Life Sciencesの推定成長EPS Q/Qは何ですか。
180 Life Sciences Corp.の推定成長EPS Q/Qは-98.15%です。
推定成長EPS Q/Qの定義は何ですか。
期待される四半期ごとのEPS成長率は、過去四半期の業績と比較して、次の四半期の企業EPSの推定増加です。
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
NASDAQのセクタHealth Careにおける推定成長EPS Q/Qの企業と比べる180 Life Sciences
180 Life Sciencesは何をしますか。
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
180 Life Sciencesと類似の推定成長eps q/q
- Hycroft Miningの推定成長EPS Q/Qは-98.72%です。
- F45 Trainingの推定成長EPS Q/Qは-98.67%です。
- Shionogi & Coの推定成長EPS Q/Qは-98.65%です。
- Biglariの推定成長EPS Q/Qは-98.49%です。
- Endava plcの推定成長EPS Q/Qは-98.48%です。
- Aarons Incの推定成長EPS Q/Qは-98.33%です。
- 180 Life Sciencesの推定成長EPS Q/Qは-98.15%です。
- Abraxas Petroleumの推定成長EPS Q/Qは-98.00%です。
- iStar Incの推定成長EPS Q/Qは-97.73%です。
- QADの推定成長EPS Q/Qは-97.66%です。
- Scorpio Bulkers Incの推定成長EPS Q/Qは-97.57%です。
- Evotec SEの推定成長EPS Q/Qは-97.56%です。
- InMed Pharmaceuticalsの推定成長EPS Q/Qは-97.28%です。